DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Visipaque (Iodixanol Intravascular) - Summary

 
 



VISIPAQUE SUMMARY

VISIPAQUE™
(iodixanol) Injection
     320

VISIPAQUE™ (iodixanol) Injection, 5,5'-[(2-hydroxy-1,3-propanediyl)bis (acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6- triiodo-1,3- benzenedicarboxamide], is a dimeric, isosmolar, nonionic, water-soluble, radiographic contrast medium with a molecular weight of 1550.

INTRA-ARTERIAL

VISIPAQUE Injection (270 mgI/mL) is indicated for intra-arterial digital subtraction angiography.

VISIPAQUE Injection (320 mgI/mL) is indicated for angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography.

INTRAVENOUS [For information on the concentrations and doses for the pediatric population see the Precautions–Pediatric Use, Clinical Pharmacology–Special Populations, and Dosage and Administration sections.]

VISIPAQUE Injection (270 mgI/mL) is indicated for CECT imaging of the head and body, excretory urography, and peripheral venography.

VISIPAQUE Injection (320 mgI/mL) is indicated for CECT imaging of the head and body, and excretory urography.


See all Visipaque indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Visipaque (Iodine Intravascular)

FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2016.05.31]
The U.S. Food and Drug Administration has approved Axumin, a radioactive diagnostic agent for injection.

Flexible future of point-of-care disease diagnostic
Source: Bird Flu / Avian Flu News From Medical News Today [2015.07.29]
The world-wide deployment of biomedical devices for health monitoring, point-of-care diagnostics and environmental sensing is hampered by their high cost that is not readily affordable for e.g.

Artificial enzymes used in wide range of household products are "potent allergens"
Source: Allergy News From Medical News Today [2016.09.22]
But no commercially available diagnostic tests to monitor this potential new health risk.

Molecular Testing of Cancers: 'Let's Try to Get It Right'
Source: Medscape Internal Medicine Headlines [2016.09.21]
Use of molecular diagnostics in cancer can be tricky, but Dr Lundberg says the pathologist can ask important questions to help guide the process.
Medscape Internal Medicine

Prenatal Ultrasound Tied to Autism Severity in At-Risk Kids
Source: Medscape Psychiatry & Mental Health Headlines [2016.09.21]
First-trimester diagnostic ultrasound has been linked to greater autism symptom severity, particularly in genetically vulnerable boys.
Medscape Medical News

more news >>

Published Studies Related to Visipaque (Iodine Intravascular)

Alcohol-based chlorhexidine vs. povidone iodine in reducing skin colonization prior to regional anesthesia procedures. [2011.07]
CONCLUSION: For skin disinfection prior to the neuraxial blockade procedure, the use of alcohol-based chlorhexidine compared with the use of povidone iodine lowered the incidence of insertion-site-colonization.

MDCT angiography for detection of pulmonary emboli: comparison between equi-iodine doses of iomeprol 400 mgI/mL and iodixanol 320 mgI/mL. [2009.06]
OBJECTIVES: To compare iomeprol 400 and iodixanol 320 in pulmonary artery MDCTA in subjects with suspected pulmonary embolism... CONCLUSION: The greater iodine delivery rate achievable with iomeprol 400 compared to iodixanol-320 at equi-iodine dose and injection rate permits consistently greater attenuation at all levels of the pulmonary arterial tree.

Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. [2006.09.05]
OBJECTIVES: This study sought to compare the nephrotoxicity of iodixanol and ioxaglate in patients with renal impairment undergoing coronary angiography. BACKGROUND: Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium (IOCM), may be less nephrotoxic than low-osmolar contrast media (LOCM) in high-risk patients... CONCLUSIONS: The IOCM iodixanol was significantly less nephrotoxic than ioxaglate, an ionic, dimeric LOCM. (The RECOVER Trial; http://clinicaltrials.gov; NCT00247325).

Intravenous contrast material administration at helical 16-detector row CT coronary angiography: effect of iodine concentration on vascular attenuation. [2005.08]
The institutional review board approved this study, and all patients gave written informed consent. One hundred twenty-five patients scheduled to undergo retrospectively electrocardiographically gated 16-detector row computed tomographic coronary angiography were prospectively randomized into the following five groups with respect to the intravenous administration of a 140-mL bolus of contrast material at 4 mL/sec: group 1 (iohexol [300 mg of iodine per milliliter]), group 2 (iodixanol [320 mg I/mL]), group 3 (iohexol [350 mg I/mL]), group 4 (iomeprol [350 mg I/mL]), and group 5 (iomeprol [400 mg I/mL])...

Coronary stent evaluation with coronary computed tomographic angiography: comparison between low-osmolar, high-iodine concentration iomeprol-400 and iso-osmolar, lower-iodine concentration iodixanol-320. [2014]
stents with MDCT-CA... CONCLUSIONS: Iodixanol-320 provides better image quality of coronary stents,

more studies >>

Reports of Suspected Visipaque (Iodine Intravascular) Side Effects

Pyrexia (10)Renal Failure Acute (10)Infusion Site Extravasation (7)Hyperkalaemia (6)Headache (6)Lactic Acidosis (6)Nausea (6)Diarrhoea (6)Abdominal Pain (5)Confusional State (5)more >>


Page last updated: 2016-09-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015